KALA BIO Sets November 3 Vote on Reverse Split Up to 1-for-300 to Regain Nasdaq Compliance
KALA is trading near its 52-week low of $0.49 (7.9% above the low) on elevated volume (2.0× avg).
Summary
KALA BIO's definitive proxy sets a November 3 vote on a reverse stock split of up to 1-for-300 to address its Nasdaq delisting notice. The board would choose the exact ratio within a 1-for-2 to 1-for-300 range.
Key Events · Corporate Governance and Compliance · KALA
-
Reverse Split Vote Set for Nov 3
Shareholders will vote on a reverse stock split at a ratio between 1-for-2 and 1-for-300, with the board choosing the exact ratio and timing. The company received a Nasdaq delisting determination on August 28, 2026.
-
19.3M Shares Outstanding
As of the September 10 record date, 19,339,786 shares were outstanding. A 1-for-300 split would reduce this to approximately 64,000 shares.
-
Board Discretion on Ratio
The board may elect not to proceed with the reverse split at all, or choose any ratio within the approved range. The wide range signals preparation for a severe price decline scenario.
-
Nasdaq Compliance Pressure
The reverse split is explicitly intended to support compliance with Nasdaq continued listing requirements after the stock traded below $1.00 for 30 consecutive business days.
Analysis · KALA · Life Sciences
KALA BIO's definitive proxy sets a November 3, 2026 shareholder vote on a reverse stock split ranging from 1-for-2 to 1-for-300, with the board holding discretion on the exact ratio. The company received a Nasdaq delisting determination on August 28 after trading below $1.00 for 30 consecutive business days, and this reverse split is the primary mechanism to regain compliance. With 19.3 million shares outstanding and a stock price around $0.53, the board is seeking maximum flexibility — a 1-for-300 split would reduce the share count to roughly 64,000 shares and mechanically lift the price well above $1.00, but at the cost of extreme illiquidity and potential further shareholder value erosion. The proxy also includes routine items: election of two Class III directors, say-on-pay, and ratification of HTL International as auditor. The reverse split proposal is the market-moving item here — approval would give the board a tool to avoid delisting, but the wide ratio range signals the company is preparing for a worst-case scenario.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KALA was trading at $0.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.8M. The 52-week trading range was $0.49 to $988.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.